Trial Profile

A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taladegib (Primary)
Indications Advanced breast cancer; Basal cell cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Eli Lilly and Company; Ignyta

Most Recent Events

26 Feb 2018 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
11 Oct 2017 Status changed from active, no longer recruiting to completed.
08 Nov 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com